Literature DB >> 15102013

Hereditary thrombophilia and fetal loss: a prospective follow-up study.

C Y Vossen1, F E Preston, J Conard, J Fontcuberta, M Makris, F J M van der Meer, I Pabinger, G Palareti, I Scharrer, J C Souto, P Svensson, I D Walker, F R Rosendaal.   

Abstract

BACKGROUND: As the placental vessels are dependent on the normal balance of procoagulant and anticoagulant mechanisms, inherited thrombophilia may be associated with fetal loss.
OBJECTIVES: We performed a prospective study to investigate the relation between inherited thrombophilia and fetal loss, and the influence of thromboprophylaxis on pregnancy outcome. PATIENTS AND METHODS: Women were enrolled in the European Prospective Cohort on Thrombophilia (EPCOT). These included women with factor (F)V Leiden or a deficiency of antithrombin, protein C or protein S. Controls were partners or acquaintances of thrombophilic individuals. A total of 191 women (131 with thrombophilia, 60 controls) had a pregnancy outcome during prospective follow-up. Risk of fetal loss and effect of thromboprophylaxis were estimated by frequency calculation and Cox regression modelling.
RESULTS: The risk of fetal loss appeared slightly increased in women with thrombophilia without a previous history of fetal loss who did not use any anticoagulants during pregnancy (7/39 vs. 7/51; relative risk 1.4; 95% confidence interval 0.4, 4.7). Per type of defect the relative risk varied only minimally from 1.4 for FV Leiden to 1.6 for antithrombin deficiency compared with control women. Prophylactic anticoagulant treatment during pregnancy in 83 women with thrombophilia differed greatly in type, dose and duration, precluding solid conclusions on the effect of thromboprophylaxis on fetal loss. No clear benefit of anticoagulant prophylaxis was apparent.
CONCLUSIONS: Women with thrombophilia appear to have an increased risk of fetal loss, although the likelihood of a positive outcome is high in both women with thrombophilia and in controls.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15102013     DOI: 10.1111/j.1538-7836.2004.00662.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  7 in total

1.  The cost-benefit ratio of screening pregnant women for thrombophilia.

Authors:  Gian Luca Salvagno; Giuseppe Lippi; Massimo Franchini; Giovanni Targher; Martina Montagnana; Massimo Franchi; Gian Cesare Guidi
Journal:  Blood Transfus       Date:  2007-11       Impact factor: 3.443

2.  Association of the R67X and W303X non-sense polymorphisms in the protein Z-dependent protease inhibitor gene with idiopathic recurrent miscarriage.

Authors:  F S AlShaikh; R R Finan; A W Almawi; F E Mustafa; W Y Almawi
Journal:  Mol Hum Reprod       Date:  2011-10-27       Impact factor: 4.025

3.  Placental dermatan sulfate: isolation, anticoagulant activity, and association with heparin cofactor II.

Authors:  Tusar K Giri; Douglas M Tollefsen
Journal:  Blood       Date:  2005-12-08       Impact factor: 22.113

4.  Association of inherited thrombophilia with recurrent pregnancy loss in palestinian women.

Authors:  N S Abu-Asab; S K Ayesh; R O Ateeq; S M Nassar; W A El-Sharif
Journal:  Obstet Gynecol Int       Date:  2011-06-14

5.  Inherited thrombophilia profile in patients with recurrent miscarriages: Experience from a tertiary care center in north India.

Authors:  Narender Kumar; Jasmina Ahluwalia; Reena Das; Meenakshi Rohilla; Sunil Bose; Hari Kishan; Neelam Varma
Journal:  Obstet Gynecol Sci       Date:  2015-11-16

6.  Etiology of Recurrent Pregnancy Loss in Saudi Females.

Authors:  Ahlam A Al-Ghamdi; Sawsan F Makhashen
Journal:  Saudi J Med Med Sci       Date:  2016-08-11

Review 7.  Overcoming heparin resistance in pregnant women with antithrombin deficiency: a case report and review of the literature.

Authors:  Panagiotis Tsikouras; Anna Christoforidou; Anastasia Bothou; Dorelia Deuteraiou; Xanthoula Anthoulaki; Anna Chalkidou; Stefanos Zervoudis; Georgios Galazios
Journal:  J Med Case Rep       Date:  2018-06-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.